Merck and Moderna have initiated a phase III randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
